Japanese drug major Daiichi Sankyo (TYO: 4568) has announced results from the global Phase IIIb ENSURE-AF study of Lixiana (edoxaban) in patients with non-valvular atrial fibrillation (NVAF) undergoing cardioversion.
Data demonstrated that the oral, once-daily drug, which is known as Savaysa in the USA, met the study’s primary endpoints, showing comparable efficacy and safety to well-managed enoxaparin/warfarin for the prevention of stroke and other blood clot complications.
The results from ENSURE-AF were presented on Tuesday at the European Society of Cardiology (ESC) Congress 2016 in Rome, and published in The Lancet. They show that Lixiana may be an effective and well-tolerated alternative to conventional treatment with enoxaparin and a vitamin K antagonist (VKA), and may allow prompt cardioversion to be performed with transoesophageal echocardiography (TEE)
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze